Top

Published in:

01-08-2000 | Adis New Drug Profile

Esomeprazole

Authors: Caroline M. Spencer, Diana Faulds

Published in: Drugs | Issue 2/2000

Abstract

▴ Esomeprazole, a new proton pump inhibitor, is the S-isomer of omeprazole and is the first such inhibitor to be developed as a single isomer.

▴ Esomeprazole provided better control of intragastric pH than omeprazole, lansoprazole and pantoprazole in trials conducted in patients with gastro-oesophageal reflux disease (GORD) or healthy volunteers (n = 20 to 115).

▴ In 2 large randomised, double-blind multicentre trials esomeprazole 20 and/or 40mg for 8 weeks produced higher healing rates of erosive oesophagitis and better symptom control than omeprazole 20mg in patients with GORD.

▴ Esomeprazole 10, 20 or 40mg once daily for 6 months maintained healing versus placebo (p < 0.001) in patients with endoscopically confirmed healed erosive oesophagitis in 2 large randomised, double-blind multicentre trials.

▴ Similarly, symptom-driven on-demand use of esomeprazole effectively controlled symptoms of GORD (heartburn) for 6 months in 2 large placebo-controlled trials.

▴ Esomeprazole-based triple therapy for 7 days was as effective for eradication of Helicobacter pylori as longer omeprazole-based therapy in 2 randomised double-blind trials including about 450 patients each. Endoscopically confirmed ulcer healing 4 weeks after treatment initiation was reported in about 90% of patients with active duodenal ulcer in both treatment groups.

▴ Esomeprazole-based triple therapy for 10 days was more effective than esomeprazole plus clarithromycin for eradication of H. pylori in 233 patients.

Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management —the Genval Workshop Report. Gut 1999; 44 Suppl. 2: S1-S16

DeVault KR, Castell DO, The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999 Jun; 94: 1434–42PubMedCrossRef

Crawley JA, Hamelin B, Gallagher E. How satisfied are chronic heartburn sufferers with the results they get from prescription strength heartburn medications [abstract]? Gastroenterology 2000; 118: A210CrossRef

Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000 Jul. In press

Hassan-Alin M, Niazi M, Röhss K, et al. Esomeprazole, the S-isomer of omeprazole, is optically stable in humans [abstract]. Gastroenterology 2000; 118 Suppl. 2: A1244-5

Astra Zeneca. Summary of Product Characteristics. Nexium tablets 20 mg and 40 mg. Mölndal, Sweden: AstraZeneca, 2000. (Data on file)

Langtry HD, Wilde MI. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs 1998; 56(3): 447–86PubMedCrossRef

Röhss K, Lundin C, Rydholm H, et al. Esomeprazole 40 mg provides more effective acid control than omeprazole 40 mg [abstract]. Presented at the XXXIInd Nordic Meeting of Gastroenterology; 2000 Jun 18–21: Göteborg, Sweden

Wilder-Smith C, Röhss K, Lundin C, et al. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A22CrossRef

10.

Röhss K, Claar-Nilsson C, Rydholm H, et al. Esomeprazole 40 mg provides more effective acid control than lanzoprazole 30 mg [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A20CrossRef

11.

Lind T, Kylebäck A, Rydberg L, et al. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of GERD [poster]. Presented at Digestive Disease Week; 2000 May 21–24: San Diego, California

12.

Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 59–67PubMedCrossRef

13.

Maton P, Vakil NB, Hwang C, et al. Safety and efficacy of long-term treatment with esomeprazole in patients with healed erosive esophagitis (EE) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A19CrossRef

14.

Andersson T, Rohss K, Hassan-Alin M, et al. Pharmacokinetics (PK) and dose-response relationship of esomeprazole (E) [abstract no. 5550]. Gastroenterology 2000; 118 (4) Suppl. 2: A1210

15.

Andersson T, Bredberg E, Sunzel M, et al. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (POA) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O) [abstract no. 5551]. Gastroenterology 2000; 118 (4) Suppl. 2: 1210

16.

Hassan-Alin M, Röhss K, Andersson T, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects [abstract no. 328]. Gastroenterology 2000; 118(4): A16CrossRef

17.

Junghard O, Hassan-Alin M, Hasselgren G. The effect of AUC and C_max of esomeprazole on acid secretion and intragastric pH [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A17CrossRef

18.

Hasselgren G, Hassan-Alin M, Andersson T, et al. Pharmacokinetics of esomeprazole are not affected by age: an assessment in the elderly [abstract]. Gastroenterology 2000; 118 Suppl. 2: A1245

19.

Sjövall H, Hagman I, Holmberg J, et al. Pharmacokinetics of esomeprazole in patients with liver cirrhosis [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A21CrossRef

20.

Kahrilas PJ, Falk G, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomised controlled trial. Aliment Pharmacol Ther 2000; In press

21.

Richter JE, Kahrilas PJ, Hwang C, et al. Esomeprazole is superior to omeprazole for healing of erosive esophagitis (EE) in GERD patients [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A20CrossRef

22.

Johnson DA, Benjamin SB, Whipple J, et al. Efficacy and safety of esomeprazole as maintenance therapy in GERD patients with healed erosive esophagitis (EE) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A17CrossRef

23.

Vakil NB, Shaker R, Hwang C, et al. Esomeprazole is effective as maintenance therapy in GERD patients with healed erosive esophagitis (EE) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A22CrossRef

24.

Talley NJ, Venables TL, Green JBR, et al. Esomeprazole 40mg and 20mg is efficacious in the lomg-term management of patients with endoscopy-negative GERD: a placebo-controlled trial of on-demand therapy for 6 months [abstract]. Gastroenterology 2000; 118: A658CrossRef

25.

Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20mg maintains symptom control in endoscopy-negative GERD: a randomized placebo-controlled trial of on-demand therapy for 6 months [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A21CrossRef

26.

Veldhuyzen van Zanten SJO, Lauritsen K, Delchier J-C, et al. 7-day triple therapy with esomeprazole, amoxicillin and clarithromycin for H. pylori (Hp) eradication in duodenal ulcer (DU) disease [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A503

27.

Tulassay Z, Kryszewski A, Ditc P, et al. 7-day treatment with esomeprazole-based triple therapy eradicates H. pylori (Hp) and heals patients with DU disease [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A502CrossRef

28.

The European Helicobacter Pylori Study Group (EHPSG). Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8–13CrossRef

29.

Fennerty MB, Laine LA, Sugg J, et al. Esomeprazole-based triple therapy is more effective than dual therapy for eradication of H. pylori (Hp) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A495CrossRef

30.

Genta RM, Magner DJ, D’Amico D, et al. Safety of long-term treatment with a new PPI, esomeprazole in GERD patients [abstract no. 326]. Gastroenterology 2000; 118(4): A16CrossRef

Title: Esomeprazole
Authors: Caroline M. Spencer
Diana Faulds
Publication date: 01-08-2000
Publisher: Springer International Publishing
Published in: Drugs / Issue 2/2000
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200060020-00006

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Esomeprazole

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2000

Viral Vectors for Gene Transfer

Esomeprazole

A Review of the Long Term Effects of Thrombolytic Agents

The Potential Role of Antisense Oligodeoxynucleotide Therapy for Cardiovascular Disease

Pioglitazone

Raloxifene